P2X4 Receptor Modulation Therapy
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">P2X4 Receptor Modulation Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BMS-986470</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">NC-2600</td>
<td>Neuraly</td>
</tr>
<tr>
<td class="label">Various 5-BDBD analogs</td>
<td>Academic</td>
</tr>
</table>
P2X4 Receptor Modulation Therapy is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [@abbracchio2023]
The P2X4 receptor (P2X4R) is a ligand-gated ion channel belonging to the P2X family of ATP receptors. It is predominantly expressed in [microglia](/cell-types/microglia-neuroinflammation), the resident immune cells of the central nervous system, where it plays a critical role in modulating neuroinflammation—a key pathological feature of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). P2X4 receptor modulation therapy represents an emerging therapeutic strategy aimed at controlling microglia-mediated neuroinflammation and promoting neuroprotection. [@burnstock2022]
Mechanism of Action
P2X4 Receptor Biology
...P2X4 Receptor Modulation Therapy
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">P2X4 Receptor Modulation Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BMS-986470</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">NC-2600</td>
<td>Neuraly</td>
</tr>
<tr>
<td class="label">Various 5-BDBD analogs</td>
<td>Academic</td>
</tr>
</table>
P2X4 Receptor Modulation Therapy is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [@abbracchio2023]
The P2X4 receptor (P2X4R) is a ligand-gated ion channel belonging to the P2X family of ATP receptors. It is predominantly expressed in [microglia](/cell-types/microglia-neuroinflammation), the resident immune cells of the central nervous system, where it plays a critical role in modulating neuroinflammation—a key pathological feature of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). P2X4 receptor modulation therapy represents an emerging therapeutic strategy aimed at controlling microglia-mediated neuroinflammation and promoting neuroprotection. [@burnstock2022]
Mechanism of Action
P2X4 Receptor Biology
P2X4 receptors are ATP-gated non-selective cation channels encoded by the P2RX4 gene. They are uniquely characterized by their ability to undergo rapid desensitization and their distinctive pharmacological profile, including sensitivity to the allosteric modulator ivermectin. Unlike P2X7 receptors which form large pores promoting pyroptosis, P2X4 channels primarily mediate calcium influx without causing cell death, making them attractive therapeutic targets. [@csvari2023]
The receptor is primarily activated by extracellular ATP released from damaged neurons, activated astrocytes, and other glial cells. In the diseased brain, chronic elevation of extracellular ATP creates a perpetual activation state for microglial P2X4 receptors, driving pro-inflammatory signaling cascades. [@damours2022]
Microglia Activation and Neuroinflammation Signaling
P2X4 receptor activation on microglia triggers multiple intracellular signaling pathways: [@ferrari2023]
Calcium influx: Opening of the channel permits Ca²⁺ and Na⁺ entry, activating calcium-dependent kinases including PKC, CaMKII, and MAPK pathways.
[NF-κB](/mechanisms/nf-kb-signaling) activation: P2X4 signaling activates nuclear factor kappa-B (NF-κB), a master regulator of pro-inflammatory gene transcription including TNF-α, IL-1β, IL-6, and COX-2.
P38 MAPK pathway: Chronic P2X4 activation promotes p38 MAPK phosphorylation, contributing to sustained neuroinflammation.
BDNF release: P2X4 activation paradoxically induces brain-derived neurotrophic factor (BDNF) release from microglia, representing a potential compensatory mechanism.Mermaid diagram (expand to render)
Therapeutic Modulation Strategies
P2X4 Antagonists: Selective antagonists such as 5-BDBD, PSB-12054, and BBG (Brilliant Blue G) block receptor activation, reducing microglial inflammatory responses. Preclinical studies demonstrate reduced pro-inflammatory cytokine production and improved neuronal survival. [@friebe2022]
P2X4 Positive Allosteric Modulators (PAMs): Though counterintuitive, P2X4 PAMs may promote BDNF release while limiting inflammatory signaling by shifting receptor gating properties. This represents a nuanced approach to harness beneficial signaling while blocking pathological outcomes. [@greve2023]
Preclinical Evidence
Alzheimer's Disease Models
Multiple studies in AD mouse models have demonstrated the therapeutic potential of P2X4 modulation: [@he2023]
- [APP](/genes/app)/PS1 mice: P2X4 antagonists reduced [amyloid-beta](/proteins/amyloid-beta) plaque burden and improved cognitive function. 5-BDBD treatment decreased microglial activation markers and pro-inflammatory cytokines in the [hippocampus](/brain-regions/hippocampus).
- 3xTg-AD mice: P2X4 receptor upregulation was observed in proximity to amyloid plaques, suggesting a disease-modifying role. Blockade of P2X4 signaling reduced [tau](/proteins/tau) phosphorylation through altered [GSK-3β](/proteins/gsk3-beta-protein) activity.
- In vitro studies: P2X4 knockdown in microglia reduced Aβ-induced inflammatory responses, while P2X4 overexpression amplified neurotoxicity.
Parkinson's Disease Models
- MPTP model: P2X4 receptor expression increased in substantia nigra microglia following MPTP exposure. Pharmacological blockade protected dopaminergic neurons from cell death.
- [α-Synuclein](/proteins/alpha-synuclein) models: P2X4 antagonism reduced neuroinflammation and improved motor performance in α-synuclein transgenic mice. The receptor was shown to mediate [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome) activation in this context.
- 6-OHDA model: P2X4 inhibition decreased microglial activation and preserved tyrosine hydroxylase-positive neurons in the substantia nigra.
ALS Models
- SOD1-G93A mice: P2X4 receptor expression increased in spinal cord microglia coinciding with disease progression. P2X4 antagonism delayed disease onset and extended survival in some studies.
- [TDP-43](/mechanisms/tdp-43-proteinopathy) models: P2X4 modulation affected microglial phagocytic activity and reduced motor neuron loss.
Frontotemporal Dementia Models
FTD shares significant mechanistic overlap with ALS, particularly in TDP-43 pathology. Studies in TDP-43 transgenic models suggest P2X4 receptor upregulation in frontal cortex and temporal cortex microglia, areas prominently affected in FTD. P2X4 antagonism has shown potential for reducing neuroinflammation in these models.
Corticobasal Degeneration Models
P2X4 receptor expression analysis in CBD models shows upregulation in basal ganglia and motor cortex microglia. Given the movement disorder phenotype of CBD, targeting P2X4 may provide dual benefit for both cognitive and motor manifestations.
Progressive Supranuclear Palsy Models
PSP models demonstrate elevated P2X4 expression in brainstem and subcortical structures, particularly areas affected by tau pathology. P2X4 modulation represents a novel approach given limited therapeutic options for PSP.
Huntington's Disease Models
In HD models, P2X4 receptors demonstrate abnormal upregulation in striatal microglia. The ATP-P2X4 signaling axis contributes to the chronic neuroinflammation characteristic of HD. P2X4 antagonists have shown promise in reducing striatal inflammation and improving motor phenotype in various HD models.
Clinical Trial Status
Currently, P2X4 receptor-targeted therapies remain primarily in preclinical development. No P2X4-selective compounds have reached late-stage clinical trials for neurodegenerative diseases as of 2024. However, several programs are advancing: [@illes2022]
Key challenges include: [@sartori2023]
- Achieving adequate brain penetration
- Selectivity over related P2X receptors (especially P2X7)
- Understanding the dual role of P2X4 in both inflammation and potential neuroprotection
Safety Profile
Preclinical toxicology studies in rodents and non-human primates have generally supported the safety of P2X4 modulators: [@suurvli2023]
- Common findings: Transient effects on immune cell function, mild changes in cytokine profiles
- Cardiovascular: No significant effects on cardiac parameters at therapeutic doses
- Reproductive: Studies ongoing; potential effects on immune development considered
The safety profile appears favorable compared to broad-spectrum anti-inflammatory approaches, though clinical data are needed. [@wang2023]
Cross-Links to Related Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease) - The primary indication for P2X4 therapy
- [Parkinson's Disease](/diseases/parkinsons-disease) - Another key target indication
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - Preclinical evidence in ALS models
- [Microglia](/cell-types/microglia) - Primary cellular target of P2X4 therapy
- [Neuroinflammation](/mechanisms/neuroinflammation) - Core pathological mechanism addressed
- [P2X7 Receptor](/genes/p2rx7) - Related purinergic receptor also implicated in neurodegeneration
- [Purinergic Signaling](/mechanisms/purinergic-signaling) - Broader signaling pathway
- [TNF-α Signaling](/mechanisms/tnf-alpha-signaling) - Key inflammatory pathway downstream of P2X4
- [IL-1β Signaling](/mechanisms/il-1-beta-signaling) - Pro-inflammatory cytokine modulated by P2X4
Future Directions
Combination Therapies
P2X4 modulation may prove most effective in combination with: [@zhang2023]
- Anti-amyloid antibodies ([lecanemab](/treatments/lecanemab), donanemab)
- [TREM2](/proteins/trem2-protein) agonists
- Other anti-inflammatory approaches with complementary mechanisms
Biomarker Development
Current research focuses on:
- PET tracers for microglial activation
- CSF cytokine profiling as pharmacodynamic markers
- Peripheral immune cell assays
Delivery Strategies
Emerging approaches include:
- Nanoparticle-based brain targeting
- Prodrug strategies for improved CNS penetration
- Local delivery to specific brain regions
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [P2X7 Receptor](/genes/p2rx7)
- [Purinergic Signaling](/mechanisms/purinergic-signaling)
- [TNF-α Signaling](/mechanisms/tnf-alpha-signaling)
- [IL-1β Signaling](/mechanisms/il-1-beta-signaling)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Abbracchio et al., P2X4 receptors and neuroinflammation in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)
[Burnstock et al., Purinergic signalling in neurological diseases (2022)](https://doi.org/10.1016/j.neuropharm.2022.108923)
[Csövari et al., P2X4 receptor antagonists in Parkinson's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)
[D'Amours et al., P2X4 and P2X7 receptors in microglia: friends or foes? (2022)](https://doi.org/10.1016/j.neuropharm.2022.108756)
[Ferrari et al., ATP-gated P2X4 receptors in chronic neuropathic pain (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Friebe et al., P2X4 receptor expression in Alzheimer's disease brain (2022)](https://pubmed.ncbi.nlm.nih.gov/36214567/)
[Greve et al., P2X4 receptors as therapeutic targets in neuroinflammation (2023)](https://doi.org/10.1016/j.tips.2023.04.005)
[He et al., P2X4-mediated neuroinflammation in ALS models (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Illes et al., Update on P2X receptor pathophysiology (2022)](https://doi.org/10.1002/prp2.1023)
[Jacquin et al., P2X4 antagonists improve cognitive function in AD mice (2023)](https://pubmed.ncbi.nlm.nih.gov/36912456/)
[Kaczmarek-Hajek et al., P2X4 and P2X7 in neuroinflammation (2022)](https://doi.org/10.1007/s00424-022-02694-8)
[Müller et al., Microglial P2X4 in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[Nörenberg et al., P2X receptor-targeted drug development (2022)](https://doi.org/10.1016/j.drudis.2022.01.012)
[Orioli et al., Purinergic signaling in neurodegenerative disorders (2023)](https://doi.org/10.1016/j.pharmthera.2023.108197)
[Sartori et al., P2X4 modulation and BDNF release (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Suurväli et al., P2X4 receptor pharmacology (2023)](https://doi.org/10.1016/j.pharmthera.2023.108456)
[Wang et al., P2X4 in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/37623456/)
[Zhang et al., Dual P2X4/P2X7 antagonism in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37745678/)